- Home
- PLX vs CRNT Comparison
PLX vs CRNT Comparison
Compare PLX & CRNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- CRNT
- Stock Information
- Founded
- PLX 1993
- CRNT 1996
- Country
- PLX United States
- CRNT Israel
- Employees
- PLX N/A
- CRNT N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- CRNT Radio And Television Broadcasting And Communications Equipment
- Sector
- PLX Health Care
- CRNT Technology
- Exchange
- PLX Nasdaq
- CRNT Nasdaq
- Market Cap
- PLX 204.9M
- CRNT 218.8M
- IPO Year
- PLX 1998
- CRNT 2000
- Fundamental
- Price
- PLX $1.85
- CRNT $2.39
- Analyst Decision
- PLX Strong Buy
- CRNT Strong Buy
- Analyst Count
- PLX 1
- CRNT 4
- Target Price
- PLX $15.00
- CRNT $5.50
- AVG Volume (30 Days)
- PLX 1.1M
- CRNT 566.2K
- Earning Date
- PLX 11-13-2025
- CRNT 11-12-2025
- Dividend Yield
- PLX N/A
- CRNT N/A
- EPS Growth
- PLX N/A
- CRNT 34.68
- EPS
- PLX 0.08
- CRNT 0.15
- Revenue
- PLX $61,948,000.00
- CRNT $380,518,000.00
- Revenue This Year
- PLX $14.53
- CRNT N/A
- Revenue Next Year
- PLX $75.77
- CRNT $7.23
- P/E Ratio
- PLX $24.02
- CRNT $16.67
- Revenue Growth
- PLX 62.79
- CRNT 5.06
- 52 Week Low
- PLX $1.01
- CRNT $1.82
- 52 Week High
- PLX $3.10
- CRNT $5.73
- Technical
- Relative Strength Index (RSI)
- PLX 38.39
- CRNT 52.29
- Support Level
- PLX $2.31
- CRNT $2.28
- Resistance Level
- PLX $2.55
- CRNT $2.61
- Average True Range (ATR)
- PLX 0.15
- CRNT 0.11
- MACD
- PLX -0.06
- CRNT -0.01
- Stochastic Oscillator
- PLX 23.70
- CRNT 36.11
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About CRNT Ceragon Networks Ltd.
Ceragon Networks Ltd is a wireless transport company in terms of unit shipments and wide distribution of its business, providing high-capacity wireless connectivity solutions to markets across various industries, mainly wireless (mobile) networks service providers. Geographically the company generates the key revenue from India. The company also has presence in North America, Europe, Africa, Asia-Pacific and Middle East, and Latin America. The company's products include IP-50 Platform, IP-20 Platform, Pointlink.